MX2021011224A - Un método para tratar la hipertensión arterial pulmonar y la hipertensión arterial pulmonar asociada y pauta posológica diaria. - Google Patents
Un método para tratar la hipertensión arterial pulmonar y la hipertensión arterial pulmonar asociada y pauta posológica diaria.Info
- Publication number
- MX2021011224A MX2021011224A MX2021011224A MX2021011224A MX2021011224A MX 2021011224 A MX2021011224 A MX 2021011224A MX 2021011224 A MX2021011224 A MX 2021011224A MX 2021011224 A MX2021011224 A MX 2021011224A MX 2021011224 A MX2021011224 A MX 2021011224A
- Authority
- MX
- Mexico
- Prior art keywords
- arterial hypertension
- pulmonary arterial
- treating
- patient
- apah
- Prior art date
Links
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 title abstract 7
- 150000003839 salts Chemical class 0.000 abstract 2
- 101001074035 Homo sapiens Zinc finger protein GLI2 Proteins 0.000 abstract 1
- 102100035558 Zinc finger protein GLI2 Human genes 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- TZSZZENYCISATO-WIOPSUGQSA-N rodatristat Chemical compound CCOC(=O)[C@@H]1CC2(CN1)CCN(CC2)c1cc(O[C@H](c2ccc(Cl)cc2-c2ccccc2)C(F)(F)F)nc(N)n1 TZSZZENYCISATO-WIOPSUGQSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962819162P | 2019-03-15 | 2019-03-15 | |
| PCT/IB2020/000177 WO2020188352A1 (en) | 2019-03-15 | 2020-03-13 | A method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension and daily dosing |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021011224A true MX2021011224A (es) | 2021-12-10 |
Family
ID=71092560
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021011224A MX2021011224A (es) | 2019-03-15 | 2020-03-13 | Un método para tratar la hipertensión arterial pulmonar y la hipertensión arterial pulmonar asociada y pauta posológica diaria. |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US11576915B2 (https=) |
| EP (1) | EP3938043A1 (https=) |
| JP (1) | JP2022525202A (https=) |
| KR (1) | KR20210139293A (https=) |
| CN (1) | CN113784717A (https=) |
| AU (1) | AU2020244278A1 (https=) |
| CA (1) | CA3133589A1 (https=) |
| MX (1) | MX2021011224A (https=) |
| WO (1) | WO2020188352A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2022507533A (ja) * | 2018-11-16 | 2022-01-18 | アルタバント・サイエンシズ・ゲーエムベーハー | 肺動脈性高血圧症および他疾患に関連する肺動脈性肺高血圧症の治療法 |
| US11607413B2 (en) * | 2019-01-30 | 2023-03-21 | Altavant Sciences Gmbh | Dosage regime and method for treating pulmonary arterial hypertension |
| US11576915B2 (en) | 2019-03-15 | 2023-02-14 | Altavant Sciences Gmbh | Method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension and daily dosing |
| WO2023062595A1 (en) * | 2021-10-14 | 2023-04-20 | Altavant Sciences Gmbh | Treatment of subjects having pulmonary arterial hypertension with rodatristat ethyl |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101815534A (zh) * | 2007-07-11 | 2010-08-25 | 莱西肯医药有限公司 | 用于治疗肺动脉高压以及相关疾病和病症的方法和组合物 |
| UA119247C2 (uk) | 2013-09-06 | 2019-05-27 | РОЙВЕНТ САЙЕНСИЗ ҐмбГ | Спіроциклічні сполуки як інгібітори триптофангідроксилази |
| US9399741B2 (en) | 2013-10-09 | 2016-07-26 | Uop Llc | Methods and apparatuses for desulfurizing hydrocarbon streams |
| KR20210102887A (ko) * | 2018-11-14 | 2021-08-20 | 알타반트 사이언시스 게엠베하 | 말초 세로토닌과 관련된 질병 또는 장애를 치료하기 위한 트립토판 하이드록실라제 1 (tph1)의 결정질 스피로사이클릭 화합물 억제제 |
| JP2022507533A (ja) * | 2018-11-16 | 2022-01-18 | アルタバント・サイエンシズ・ゲーエムベーハー | 肺動脈性高血圧症および他疾患に関連する肺動脈性肺高血圧症の治療法 |
| US20200188399A1 (en) | 2018-12-17 | 2020-06-18 | Altavant Sciences Gmbh | Method for treating interstitial lung disease |
| WO2020128608A1 (en) * | 2018-12-17 | 2020-06-25 | Altavant Sciences Gmbh | Compound for use in a method for treating sarcoidosis-associated pulmonary hypertension |
| US11607413B2 (en) | 2019-01-30 | 2023-03-21 | Altavant Sciences Gmbh | Dosage regime and method for treating pulmonary arterial hypertension |
| US11576915B2 (en) | 2019-03-15 | 2023-02-14 | Altavant Sciences Gmbh | Method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension and daily dosing |
-
2020
- 2020-03-13 US US16/818,236 patent/US11576915B2/en active Active
- 2020-03-13 AU AU2020244278A patent/AU2020244278A1/en not_active Abandoned
- 2020-03-13 CA CA3133589A patent/CA3133589A1/en active Pending
- 2020-03-13 CN CN202080033296.0A patent/CN113784717A/zh active Pending
- 2020-03-13 JP JP2021555469A patent/JP2022525202A/ja active Pending
- 2020-03-13 EP EP20732658.8A patent/EP3938043A1/en not_active Withdrawn
- 2020-03-13 MX MX2021011224A patent/MX2021011224A/es unknown
- 2020-03-13 WO PCT/IB2020/000177 patent/WO2020188352A1/en not_active Ceased
- 2020-03-13 KR KR1020217031156A patent/KR20210139293A/ko not_active Abandoned
-
2023
- 2023-01-04 US US18/149,992 patent/US20240024316A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US11576915B2 (en) | 2023-02-14 |
| US20200289510A1 (en) | 2020-09-17 |
| AU2020244278A1 (en) | 2021-09-30 |
| JP2022525202A (ja) | 2022-05-11 |
| KR20210139293A (ko) | 2021-11-22 |
| EP3938043A1 (en) | 2022-01-19 |
| US20240024316A1 (en) | 2024-01-25 |
| WO2020188352A1 (en) | 2020-09-24 |
| CN113784717A (zh) | 2021-12-10 |
| CA3133589A1 (en) | 2020-09-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021011224A (es) | Un método para tratar la hipertensión arterial pulmonar y la hipertensión arterial pulmonar asociada y pauta posológica diaria. | |
| MX2008013578A (es) | Derivados de tieno [3,2-d]pirimidina utiles como inhibidores de fosfatidilinositol 3-cinasa(p13k). | |
| GB0423653D0 (en) | Pharmaceutical compounds | |
| CA2549801A1 (en) | Use of treprostinil to improve kidney functions | |
| ZA200500887B (en) | Use of and some novel imidazopyridines. | |
| WO2020157577A8 (en) | A dosage regime and method for treating pulmonary arterial hypertension with rodatristat ethyl | |
| WO2001039762A3 (en) | Use of taurolidine or taurultam for the manufacture of a medicament for the treatment of tumors of the central nervous system | |
| NZ592608A (en) | Benzoxazole kinase inhibitors and methods of use | |
| AU2020278236A8 (en) | Methods of treating Sjögren's Syndrome using a Bruton's tyrosine kinase inhibitor | |
| MX2011009709A (es) | Compuestos para el tratamiento de la inflamacion y del dolor. | |
| WO2007149283B1 (en) | Use of kw-3902 for achieving diuresis in patients with congestive heart failure and acute fluid overload | |
| EP4599894A3 (en) | Methods of treating chronic spontaneous urticaria using a bruton s tyrosine kinase inhibitor | |
| MX2022008342A (es) | Metodos para tratar afecciones relacionadas con el receptor de s1p1. | |
| EP1594885B8 (de) | Medikament zur wachstumsinhibierung von tumoren | |
| WO2020219645A3 (en) | Methods for reducing the weight loss or increasing the weight of a feline in need thereof | |
| MX2022006083A (es) | Metodos para tratar afecciones relacionadas con el receptor s1p1. | |
| MX2023012039A (es) | Compuestos bicíclicos fusionados sustituidos como inhibidores de parp y uso de estos. | |
| RU2015119377A (ru) | Лекарственные формы леводопы для быстрого купирования болезни паркинсона | |
| NZ587941A (en) | Methods to inhibit tumor cell growth by using lansoprazole | |
| US20030162786A1 (en) | Use of cysteine derivatives for the preparation of a medicament intended to treat pathologies which result from the formation of the heterotrimeric G protein | |
| WO2020128614A8 (en) | Method for treating interstital lung disease | |
| MX2025005154A (es) | Formulaciones orales compactables de ibutamoren. | |
| TW200503666A (en) | Treatment of type 1 diabetes with pde5 inhibitors | |
| WO2022040369A8 (en) | Methods for treating remitting multiple sclerosis | |
| CA2544432A1 (en) | Stable pharmaceutical composition comprising granulocyte-colony stimulating factor |